Systems Biological Assessment of the Durability of Vaccine Responses

STUDY00004930

The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vaccination is known to induce durable protection over several decades. In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection. Currently, the duration of immune protection for new vaccines is difficult to predict during vaccine product development and can only be ascertained by a "wait and see" approach. This is due, in part, to the fact that some of the signals that activate a durable immune system protection remain unknown. This study aims to provide a better understanding of this problem by vaccinating willing participants with either the FDA-approved yellow fever vaccine or the quadrivalent influenza vaccine and collecting baseline and follow-up biologic samples to compare how the immune system reacts.

2023-04-11

2025-09-30

2025-09-30

Recruiting

Early phase I

60

Inclusion Criteria: * Able to understand and give informed consent. * Age 18-50 years. * Participants agree not to take any live vaccines 30 days before or after (14 days for inactivated) vaccination. * Women of child bearing potential must agree to use effective birth control for the first 3 months of the study. A negative urine pregnancy test must be documented prior to vaccination and prior to tissue sampling procedures. Exclusion Criteria: * History of allergy or serious adverse reaction, including Guillain-Barré syndrome, to a vaccine or vaccine products. * History of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study. * History of Hepatitis B or Hepatitis C infection. * Chronic clinically significant medical problems that could affect the immune response, require medication that would affect the immune response, or have signs or symptoms that could be confused with reactions to vaccination, including (but not limited to): 1. Insulin dependent diabetes 2. Severe heart disease (including arrhythmias) 3. Severe lung disease 4. Severe liver disease 5. Severe kidney disease 6. Grade 4 hypertension (\*Grade 4 hypertension per CTCAE criteria is defined as life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit)) * Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of uncontrolled autoimmune disorder. * Pregnancy or breast feeding, or plans to become pregnant in the first 3 months of study participation. * Receipt of blood products or immune globulin product within the prior 3 months. * Active duty military. * History of excessive alcohol consumption, drug use, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial. Additional Exclusion Criteria for YF-17D Arm * History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, or Japanese encephalitis vaccination or infection. * Previous residence in a country where there is a risk of yellow fever virus (YFV) transmission * History of allergy to eggs, chicken, or gelatin. Additional Exclusion Criteria for QIV Arm * History of influenza infection within the same influenza season.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ESTIMATED'}}

2024-05-16